Date: 22 April 2025 Venue: Keidanren Kaikan



The 14<sup>th</sup> APAC

# MQS Session GMP Inspection Reliance



### **GMP Inspection Reliance**



#### **Speakers and Chairs**



Speaker & Panelist Hng Kim Mi (NPRA)



Speaker & Panelist Lim Li Lian (HSA)



Chair Michihiro Imada (PMDA)



Speaker & Panelist Kentaro Hara (PMDA)



Chair Miyako Maruyama (JPMA)



Speaker Makoto Ono (JPMA)





#### **Our Expectation**

- The promotion of GMP Inspection Reliance will avoid duplicate inspections and allow for optimal resource allocation based on risk.
- The realization of GMP Inspection Reliance will generate more resources for other activities.
- Patient benefit : Early Access and High Quality



#### **Question 1**

# What are key points to promote/hinder GMP Inspection Reliance?



**Question 2** 

What is required to realize GMP Inspection Reliance, between industries and regulatory authorities, or among relevant regulatory authorities?

- especially in cases where GMP issues arise once GMP Inspection Reliance is achieved, how should these be handled?



**Question 3** 

# What GMP compliance evidence is acceptable once GMP Inspection Reliance achieved?



**Question 4** 

## What are the future benefits for the patients and companies of your economy once GMP Inspection Reliance achieved?



#### **Question 5**

#### What benefits would there be for Asia, that materialize GMP inspection reliance in Asia?

# **GMP Inspection Reliance**



#### Conclusion

• GMP Inspection Reliance avoids duplicate inspections and optimize resource allocation based on risk. For low-risk sites, GMP certificates may be accepted instead of having to perform duplicate inspections. GMP inspection reliance support innovation by generating resources for both regulatory authorities and companies.

 Promoting GMP Inspection Reliance requires mutual understanding and trust among authorities through communication, training, assessment. It will lead to maintain a high level of GMP standards in each economy.

The realization of GMP inspection reliance will contribute to early approval by conducting GMP assessments with minimal resources and time, enabling patients to access high-quality medicines earlier.